Research graph
References from Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults. Local targets link to admitted publications; unresolved targets remain external evidence.
Extending human IgG half‐life using structure‐guided design
2018 · External reference
Monoclonal antibodies for prevention and treatment of COVID‐19
10.1001/jama.2020.10245 · 2020 · External reference
The SARS‐CoV‐2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half‐life in humans
10.1126/scitranslmed.abl8124 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Subcutaneous REGEN‐COV antibody combination to prevent Covid‐19
10.1056/nejmoa2109682 · 2021 · External reference
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID‐19 over an 8‐month period: a randomised, double‐blind, placebo‐controlled trial
10.1016/s1473-3099(22)00416-9 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
High‐throughput engineering of the mouse genome coupled with high‐resolution expression analysis
10.1038/nbt822 · 2003 · External reference
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
10.1073/pnas.1323896111 · 2014 · External reference
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
10.1073/pnas.1324022111 · 2014 · External reference
Unresolved reference
External reference
10.1128/aac.01714‐16
10.1128/aac.01714‐16 · External reference
A phase 1 randomized, double‐blind, placebo‐controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy adults
10.1002/cpdd.883 · 2021 · External reference
10.1128/aac.01020‐16
10.1128/aac.01020‐16 · External reference
A novel investigational Fc‐modified humanized monoclonal antibody, motavizumab‐YTE, has an extended half‐life in healthy adults
10.1128/aac.01285-13 · 2013 · External reference
Safety, tolerability and pharmacokinetics of half‐life extended severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibodies AZD7442 (tixagevimab‐cilgavimab) in healthy adults
10.1093/infdis/jiad014 · 2023 · External reference
P‐1605. A phase 1, randomized, double‐blind, placebo‐controlled study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of REGN17092, an YTE modified anti‐SARS‐COV‐2 (COVID‐19) monoclonal antibody in adult healthy volunteers
2026 · External reference
Unresolved reference
External reference
Translational approach for predicting human pharmacokinetics of engineered therapeutic monoclonal antibodies with increased FcRn‐binding mutations
10.1007/s40259-022-00566-2 · 2023 · External reference
REGEN‐COV(®) antibody cocktail bioanalytical strategy: comparison of LC‐MRM‐MS and immunoassay methods for drug quantification
10.4155/bio-2021-0190 · 2021 · External reference
10.1201/b14095
10.1201/b14095 · 1982 · External reference
Population pharmacokinetics of therapeutic monoclonal antibodies
10.2165/11535960-000000000-00000 · 2010 · External reference
Population pharmacokinetics of casirivimab and imdevimab in pediatric and adult non‐infected individuals, pediatric and adult ambulatory or hospitalized patients or household contacts of patients infected with SARS‐COV‐2
10.1007/s11095-024-03764-5 · 2024 · External reference
REGN‐COV2, a neutralizing antibody cocktail, in outpatients with Covid‐19
10.1056/nejmoa2035002 · 2021 · External reference
Unresolved reference
External reference
Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human
10.4161/mabs.23684 · 2013 · External reference
Randomized, double‐blind, placebo‐controlled, single‐ascending‐dose study of the penetration of a monoclonal antibody combination (ASN100) targeting Staphylococcus aureus cytotoxins in the lung epithelial lining fluid of healthy volunteers
10.1128/aac.00350-19 · 2019 · External reference
Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk‐binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks
10.1016/j.ebiom.2016.02.021 · 2016 · External reference
A quantitative modeling and simulation framework to support candidate and dose selection of anti‐SARS‐CoV‐2 monoclonal antibodies to advance bamlanivimab into a first‐in‐human clinical trial
10.1002/cpt.2459 · 2022 · External reference
Unresolved reference
External reference
Safety, tolerability, and pharmacokinetics of the long‐acting SARS‐CoV‐2–neutralizing monoclonal antibody combination AZD7442 (tixagevimab/cilgavimab) in healthy Chinese adults
10.1002/cpdd.1583 · 2025 · External reference
